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OBJECTIVEdTo investigate the association between glycemic variability (GV) and both
length of stay (LOS) and 90-day mortality in noncritically ill hospitalized patients.
RESEARCH DESIGN AND METHODSdThis study retrospectively analyzed 4,262
admissions to the general medicine or surgery services during a 2 year period. Patients with
point-of-care glucose monitoring and a minimum of two glucose values per day on average were
selected. GV was assessed by SD and coefﬁcient of variation (CV). Data were analyzed with linear
and logistic multivariate regression analysis in separate models for SD and CV. Analysis was
performed with generalized estimating equations to adjust for correlation between multiple
admissions in some individual cases.
RESULTSdAfter exclusions, 935 admissions comprised the sample. Results of adjusted anal-
ysis indicate that for every 10mg/dL increase in SD and 10–percentage point increase in CV, LOS
increased by 4.4 and 9.7%, respectively. Relative risk of death in 90 days also increased by 8% for
every 10-mg/dL increase in SD. These associations were independent of age, race, service of care
(medicine or surgery), previous diagnosis of diabetes, HbA1c, BMI, the use of regular insulin as a
sole regimen, mean glucose, and hypoglycemia occurrence during the hospitalization.
CONCLUSIONSdOur results indicate that increased GV during hospitalization is indepen-
dently associated with longer LOS and increased mortality in noncritically ill patients. Prospec-
tive studies with continuous glucose monitoring are necessary to investigate this association
thoroughly and to generate therapeutic strategies targeted at decreasing GV.
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Inpatient hyperglycemia is common,and it has been associated with in-creased morbidity and mortality in
patients with and without diabetes (1–
7). In the intensive care unit (ICU) setting,
hypoglycemia has also been indepen-
dently associated with a signiﬁcant in-
crease in mortality (8–10). Recently, a
third metric of glucose control, known
as glycemic variability (GV), has been
proposed to be additionally impli-
cated in the disease-associated process of
dysglycemia (11).
GV refers to ﬂuctuations of blood
glucose values around the mean and has
been posited as a novel marker for poor
glycemic control (12,13). In vitro and hu-
man studies suggest that high GV leads to
greater oxidative stress than does sus-
tained hyperglycemia (14,15). Studies of
ICU patients have consistently demon-
strated that increased GV is indepen-
dently associated with higher mortality
(16–19). Notably, results from a large
multicenter study concluded that GV
was a stronger predictor of ICU mortality
than was mean glucose concentra-
tions (20).
Although there is no consensus as to
the best method to determine GV in
hospitalized patients, the use of SD of
glucose values has been well validated by
previous ICU studies (16,20). Coefﬁcient
of variation (CV) has also been suggested
as a strong independent index formeasur-
ing GV because it corrects for mean glu-
cose levels (21,22).
Despite substantial scientiﬁc evidence
from the ICU, no previous studies have
investigated the association between GV
and clinical outcomes in patients admitted
to the general medical and surgical wards.
The purpose of this study was therefore to
investigate the association between GV and
length of stay (LOS) and 90-day mortality
in noncritically ill hospitalized patients.
We hypothesize that increased GV in this




Study design and patient selection
We performed a retrospective cohort
study that included patients admitted to
the acute non-ICU medicine and surgery
services of the Stratton Veterans Affairs
Medical Center in Albany, NY, between
January 2008 and January 2010.
Approval of the institutional review
board was obtained. The initial query
included all patient admissions with
available blood glucose concentration
from any of the admitting hospital ser-
vices (n = 4,262).
Exclusion criteria applied to the study
included the following: patients admitted
to or transferred from the ICU and long-
term care wards (n = 1,624); patient ad-
missions with very long hospital stays
(.60 days), to avoid patients not acutely
ill (n = 5); patient admissions with no
point-of-care glucose monitoring (n =
1,456); patient admissions with fewer
than two glucose values per day of hospi-
talization on average (n = 240); and
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patient admissions with inconsistent date
of death information (n = 2). Patients who
were hospitalized more than once had
each admission counted separately.
Data collection
Data were extracted from the VISN 2
Veterans Health Information Systems and
Technology Architecture (VistA) and the
Veterans Affairs Regional Data Ware-
house (VARDW). Data from VistA were
collected via a Mumps program routine
and imported as a spreadsheet to Micro-
soft SQL Server Database. They were
merged with the VARDW data by means
of speciﬁc Structured Query Language
queries.
Blood glucose concentrations were
measured in capillary blood obtained by
ﬁnger stick with a point-of-care device
(ACCU-CHEK Inform system). We also
made use of glucose determinations per-
formed on venous blood in the central
hospital laboratory. In an attempt to
correct for false high or low readings,
duplicates and glucose values that were
followed by a conﬁrmatory reading
within 5 min were removed from the
sample.
Outcome measures included LOS
and mortality. LOS was calculated by
the number of days from admission date
to discharge or death date. Mortality was
deﬁned as in-hospital death or death
within 90 days from discharge.
Glucose metrics and statistical
analysis
Mean in-hospital glucose (MHG) was
calculated from all glucose readings avail-
able during each individual hospitaliza-
tion. In addition, to correct for variation
in the number of readings each day, a
mean patient-day glucose (MDG) was
calculated as the average of daily mean
glucose values during hospitalizations.
Hypoglycemia was deﬁned as any episode
of blood glucose ,70 mg/dL during the
hospital stay.
We quantiﬁed GVwith SD and CV for
the data set of all available glucose read-
ings for each admission. CV was deﬁned
as the ratio of SD to MHG, expressed as a
percentage. Linear and modiﬁed Poisson
regression analyses were used to assess
associations between measures of GV and
the two outcomes. The associations be-
tween GV and the outcome measures
were assessed in separate models for SD
and CV. Other variables assessed for
potential confounding included age,
race, sex, hospital service (medicine or
surgery), previous diagnosis of diabetes,
glycosylated hemoglobin (HbA1c) ob-
tained within 3 months from admission,
BMI, Charlson comorbidity index (CCI),
hypoglycemia, MHG, MDG, and use of
human regular insulin as the sole regi-
men for glycemic control during the
hospitalization.
Analyses were performed with gener-
alized estimating equations to adjust for
correlation between multiple admissions
in some cases. Log-transformed LOS and
90-day mortality were the dependent
variables. A linear link and normal error
structure were used for the LOS, and a
logit link and binomial error structure
were used for 90-day mortality.
A bivariate analysis was initially per-
formed to identify signiﬁcant associations
between individual variables and the two
outcome measures. Those variables for
which P # 0.1 were subsequently in-
cluded in multivariate models to assess
whether the associations between SD
(SD model) or CV (CV model) and LOS
and mortality were independent of other
variables. In the multivariate models,
those variables with a level of statistical
signiﬁcance of P , 0.05 were subse-
quently retained through backward
elimination.
To investigate the potential inﬂuence
of hypoglycemia on the associations be-
tween GV and LOS and mortality, sepa-
rate additional models that did not correct
for hypoglycemia were created for CV and
SD. Moreover, regression analyses were
performed to assess the risk of hypogly-
cemia occurrence in those patient admis-
sions with high CV and high SD of
glucose. Subgroup analyses were also
performed by SD and CV categories
within patient admissions with adequate
glycemic control (MHG 90–180 mg/dL)
and those with signiﬁcant hyperglycemia
(MHG .180 mg/dL).
Because LOS was not normally dis-
tributed, it was log-transformed, and the
results presented and interpreted accord-
ingly. Statistical software STATA 11.0 was
used for all analyses.
RESULTS
Subjects
After exclusion criteria were applied, the
ﬁnal sample consisted of 935 hospital
admissions comprising 620 individual
patients. Table 1 summarizes the charac-
teristics of the study subjects and the re-
sults of bivariate analyses. The patient
population was composed mainly of
elderly, white male subjects, most of
whomwere admitted to the acute medical
service. Diabetes had been diagnosed in
801 patients (85.7%) before admission.
Study patients had on average 3.56 6
0.9 glucose readings per day. The mean
LOS was 5.72 6 6.37 days, and there
were 120 deaths (12.83%) within 90
days of discharge.
Length of stay
Table 1 summarizes associations between
the examined variables and LOS. Higher
SD and CV of glucose were both signiﬁ-
cantly associated with longer LOS. LOS
increased by 6.4% with each 10 mg/dL
increment in SD of glucose (95% CI
4.4–8.3%, P , 0.001) and by 16.5%
with each 10–percentage point increment
in CV of glucose (12.1–20.9%, P ,
0.001). In addition, LOS increased by
6.6% with each 10-year increment in
age (1.3–12.0%, P = 0.015), and LOS of
patients with hypoglycemia was 56.2%
longer than that of those without (42.8–
69.6%, P, 0.001). A lower BMI was also
signiﬁcantly associated with longer LOS.
None of the other variables, including
sex, race, previous diagnosis of diabetes,
HbA1c, service (medicine versus surgery),
MDG, MHG, CCI, or the use of human
regular insulin as a sole regimen, had a
signiﬁcant association with LOS.
Table 2 shows the adjusted associa-
tions between both GV measures and
LOS after correction for age and hypogly-
cemia in separate models. In the SD
model, the association between SD of glu-
cose and LOS was reduced to 4.4% (95%
CI 2.4–6.3%, P , 0.001), that of hypo-
glycemia decreased to 47.3% (33.3–
61.2%, P , 0.001), and that of age
decreased to 5.1% (0.2–10.1%, P =
0.043). In the SD model that did not cor-
rect for hypoglycemia, the associations of
SD and age with LOS decreased slightly
relative to the results of the bivariate anal-
ysis (5.9%, 0.8–11.0%, P , 0.001 vs.
6.3%, 4.3–8.2%, P, 0.001 respectively).
In the CV model, the association between
CV of glucose and LOS decreased to 9.7%
(4.7–14.8%, P , 0.001) and that of hy-
poglycemia to 40.5% (24.7–56.3%, P ,
0.001). Age no longer had a signiﬁcant
association with LOS in that model.
Mortality
In the bivariate analysis, age, a lower BMI,
admission to the medical service, higher
CCI, hypoglycemia, and both SD and CV
of glucose were signiﬁcantly associated
with increased 90-day mortality (Table 1).
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The risk of death within 90 days increased
by 10% with each 10 mg/dL increment in
SD of glucose (risk ratio [RR] 1.10 [95%CI
1.04–1.16], P , 0.001) and by 21% with
each 10–percentage point increment in CV
of glucose (RR 1.21 [1.07–1.35], P =
0.002). Variables without a signiﬁcant as-
sociation with mortality included sex, race,
previous diagnosis of diabetes, HbA1c,
MHG, MDG, and regular insulin as sole
in-hospital regimen.
Aftermultivariate adjustment (Table 2),
age, lower BMI, admission to the medical
service, and SD of glucose remained
as independent predictors of 90-day
mortality in the SD model. The risk of
increased mortality in 90 days changed
to 8% with every 10 mg/dL increment
in SD of glucose (RR 1.08 [95% CI
1.02–1.14], P = 0.005). Although hypo-
glycemia no longer retained a signiﬁcant
association with increased mortality when
introduced into the SD model, a small
reduction of the association between SD
and mortality was noted (RR 1.07 [1.01–
1.13], P = 0.022). Similarly, in the CV
model that corrected for hypoglycemia,
CV of glucose and hypoglycemia were
no longer independent predictors of mor-
tality, whereas age, BMI, and admission to
the medical service remained signiﬁcant
predictors. In the CVmodel that corrected
for age, BMI, and hospital service, but not
for hypoglycemia, however, CV remained
signiﬁcantly associated with increased 90-
day mortality, which rose by 14% with
each 10–percentage point increment in
CV of glucose (RR 1.14 [1.01–1.29], P =
0.037).
Table 1dSample characteristics and bivariate analysis on LOS and 90-day mortality (n = 935)
Variable Value
Change in LOS 90-Day mortality risk
% (95% CI) P RR (95% CI) P
Age (years)† 69.8 6 11.2 6.6 (1.3–12.0) 0.015* 1.59 (1.24–2.05) ,0.001*
Sex (male) 895 (95.7) 24.4 (232.2 to 23.5) 0.759 0.72 (0.34–1.54) 0.400
Race (white)‡ 922 (89.8) 9.9 (210.5 to 30.4) 0.340 1.08 (0.56–2.09) 0.811
PDD 801 (85.7) 212.3 (228.9 to 4.3) 0.146 1.17 (0.67–2.05) 0.579
HbA1c (%)x 7.60 6 1.9 1.7 (21.4 to 4.8) 0.287 1.02 (0.91–1.14) 0.727
Surgical service 171 (18.2) 9.7 (26.3 to 25.8) 0.235 0.28 (0.12–0.63) 0.002*
Medical service 764 (81.7) Reference Reference
BMI (kg/m2)| 30.0 6 7.9 29.3 (218.1 to 20.5) 0.038* 0.58 (0.43–0.80) 0.001*
HRI 99 (10.6) 2.8 (25.9 to 11.5) 0.527 0.88 (0.62–1.23) 0.444
CCI
0 353 (36.8) Reference Reference
1 206 (24.5) 210.7 (226.4 to 5.0) 0.181 1.05 (0.60–1.87) 0.856
$2 401 (41.8) 4.5 (29.9 to 19) 0.537 1.72 (1.09–2.72) 0.020*
Hypoglycemia{ 228 (24.4) 56.2 (42.8–69.6) ,0.001* 1.73 (1.21–2.47) 0.002*
MHG (mg/dL) 182.4 6 56.9 20.06 (20.16 to 0.03) 0.201 1.00 (1.00–1.00) 0.139
MDG (mg/dL) 182.6 6 56.7 20.1 (20.2 to 20.004) 0.059 1.00 (1.00–1.00) 0.181
Glucose SD (mg/dL)# 57.9 6 29.3 6.4 (4.4–8.3) ,0.001* 1.10 (1.04–1.16) ,0.001*
Glucose CV (%)** 31.9 6 13.4 16.5 (12.1–20.9) ,0.001* 1.21 (1.07–1.35) 0.002*
Results are presented as mean 6 SD or n (%) except as speciﬁed otherwise. HRI, human regular insulin (as sole regimen during hospitalization); PDD, previous
diabetes diagnosis (before admission). *P , 0.05. †Per 10-year increment in age. ‡White race as compared with African American, Hispanic, Paciﬁc Islander, and
other unspeciﬁed. xPer each percentage point in HbA1c 7.6% = 60mmol/mol. |Per every 10 kg/m2 increment in BMI.{Hypoglycemia is deﬁned as any documented in-
hospital episode of glucose, 70mg/dL, and effect is compared with subjects with no hypoglycemia. #Per 10mg/dL increment in SD of glucose. **Per 10–percentage
point increment in CV of glucose.
Table 2dAssociations between GV (SD and CV) and LOS and 90-day mortality (adjusted)
Variable
Change in LOS (%) 90-Day mortality (RR [95% CI])
SD model† SD model†‡ CV modelx SD model† SD model†‡ CV modelx CV model‡x
GV 4.4 (2.4–6.3) 6.3 (4.3–8.2) 9.7 (4.7–14.8) 1.07 (1.01–1.13) 1.08 (1.02–1.14) 1.08 (0.93–1.24)* 1.14 (1.01–1.29)
Age| 5.1 (0.2–10.1) 5.9 (0.8–11.0) d 1.43 (1.12–1.82) 1.43 (1.12–1.83) 1.42 (1.11–1.82) 1.42 (1.11–1.82)
BMI{ d d 0.68 (0.50–0.93) 0.68 (0.50–0.92) 0.68 (0.50–0.93) 0.68 (0.50–0.93)
Service
Medicine Reference Reference Reference Reference Reference Reference Reference
Surgery d d d 0.37 (0.16–0.85) 0.36 (0.16–0.84) 0.35 (0.15–0.82) 0.35 (0.15–0.81)
Hypoglycemia
Absent Reference d Reference d d Reference d
Present# 47.3 (33.3–61.2) d 40.5 (24.7–56.3) 1.36 (0.95–1.94)* d 1.38 (0.92–2.05)* d
*P. 0.05; for all other values, P, 0.05. †Per every 10 mg/dL increment of SD. ‡Not correcting for hypoglycemia. xPer every 10–percentage point increment of CV.
|Per every 10-year increment.{Per every 10 kg/m2 increment in BMI. #Hypoglycemia is considered to be present with any documented in-hospital episode of glucose
,70 mg/dL.
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Subgroup analyses
Analyses examining the association be-
tween both GV measures and hypoglyce-
mia are presented in Table 3. The risk of
hypoglycemia increased by 65%per every
10–percentage point increase in CV of
glucose (RR 1.65 [95% CI 1.48–1.85],
P , 0.001) and by 14% per every 10
mg/dL increase in SD of glucose (RR 1.14
[1.11–1.18], P , 0.001). In addition, the
likelihood of hypoglycemia rose incremen-
tally within each CV and SD tertile.
Figure 1 illustrates the associations
between both SD and CV of glucose
with mean LOS (days) and 90-day mor-
tality (%) after stratiﬁcation for MHG.
Mean LOS and mortality rose incremen-
tally with SD and CV. This trend was seen
in patients with MHG suggestive of ade-
quate glycemic control (90–180 mg/dL)
as well as in those subjects with MHG
consistent with signiﬁcant hyperglycemia
($180mg/dL). Linear regression analyses
showed that these trends were statistically
signiﬁcant for all series except for the 90-
day mortality in the MHG $180 mg/dL
group for both SD and CV.
CONCLUSIONSdOur study aimed
to determine the associations between
GV and both LOS and 90-day mortality
in medicine and surgery patients in the
non-ICU setting. We found a signiﬁcant
association between high GV and longer
LOS and increased 90-day mortality. This
association was not signiﬁcantly inﬂu-
enced by age, race, service of care (med-
icine or surgery), a previous diagnosis of
diabetes, HbA1c, BMI, or the use of regu-
lar insulin as a sole regimen during the
hospitalization. Furthermore, this associ-
ationwas noted to be independent both of
glycemic control (mean glucose) and of
hypoglycemia.
Several previous studies have re-
ported on the negative association found
between increased GV and morbidity
and mortality in critically ill patients,
such as those with sepsis and congestive
heart failure (16–19). Egi et al. (20) con-
cluded from a large multicenter ICU
study that GV was a stronger predictor of
mortality than mean glucose levels. In
agreement with these results, neither
mean glucose during hospital stay nor
mean patient-day glucose was directly as-
sociated with longer LOS or mortality
in this study. Additionally, in accor-
dance with the work of Krinsley (16) and
Hermanides et al. (19), the added nega-
tive effects with increasing GV tertiles
seen in our sample were evident in pa-
tients with adequate glycemic control as
well as in those with signiﬁcant hypergly-
cemia (Fig. 1).
The association between hypoglyce-
mia and poor clinical outcomes in hospi-
talized patients has been well established
(8–10,23,24). In this study, hypoglyce-
mia was found to be signiﬁcantly and in-
dependently associated with increased
LOS. In addition, our results suggest
that hypoglycemia has a modifying effect
on the associations between GV and the
examined outcomes, indicating that it is
at least partially implicated in the causal
pathway of GV and increased LOS and
mortality. This inﬂuence seems to differ,
however, according to which GVmeasure
is used (SD or CV).
Although a noticeable attenuation in
the association between SD and LOS was
seen after adjustment for hypoglycemia
(reduction from 6.3 to 4.4% increase in
LOS per every 10 mg/dL increment in SD),
there was no signiﬁcant change in the
association between SD and mortality.
Conversely, the associations between CV
and both LOS and mortality were signif-
icantly affected after adjustment for hy-
poglycemia. The association with LOS
was considerably diminished (reduction
from 16.5 to 9.7% increase in LOS per
every 10 percentage point increase in CV),
and in the multivariate analyses for mor-
tality both CV and hypoglycemia were
rendered not signiﬁcant when the two
variables were simultaneously retained in
the model (Table 2).
The CV has been proposed to be a
strong predictor of, and closely related to,
hypoglycemia (25). In our study, patient
admissions with increased CV were sig-
niﬁcantly more likely to develop hypogly-
cemia than were those with increased SD
(Table 3). Given that CV is directly pro-
portional to SD and inversely propor-
tional to mean glucose, hypoglycemia is
expected to naturally occur in subjects
with high SD and low mean (high CV).
Thus, as suggested by our results, adjust-
ing for hypoglycemia when using CVmay
not be methodologically appropriate and
may lead to overadjustment. Alterna-
tively, SD of glucose might be a better
metric than CV when the potential effects
of GV need to be separated from those of
hypoglycemia.
Reports based on ICU patients have
used other methods to assess more ac-
curately patterns of GV over time, such
as mean amplitude of glycemic excur-
sions (MAGE) and mean absolute glu-
cose rate of change (MAG) (19,22).
Baghurst et al. (26) showed that as glu-
cose values separate in time (.4 h be-
tween readings), the use of MAGE
becomes less reliable than SD to estimate
GV. Similarly, Harmsen et al. (27) found
that using MAG to estimate GV accu-
rately requires similar glucose measure-
ment frequencies, which were not
available in our sample.
Focusing on patients from general
wards rather than ICU is an important
strength of our study. We believe this
provides a novel perspective of the im-
plications that GV might have in this
speciﬁc patient population. Despite this
population being the largest in most
hospitals, it has not been as studied in
terms of glycemic control and GV. An-
other strong point of this study is that the
mean number of daily glucose measure-
ments used for analysis (3.56 6 0.9) al-
lowed enough data for accurate assessment
Table 3dAssociations between GV (SD and CV) and hypoglycemia
Association RR P 95% CI
CV and hypoglycemia*
CV† 1.65 ,0.001 1.48–1.85
1st tertile† Reference Reference Reference
2nd tertile †‡ 10.40 ,0.001 4.21–25.69
3rd tertile†‡ 34.3 ,0.001 14.29–82.37
SD and hypoglycemia*
SDx 1.14 ,0.001 1.11–1.18
1st tertilex Reference Reference Reference
2nd tertile‡x 2.15 ,0.001 1.46–3.18
3rd tertile‡x 3.98 ,0.001 2.79–5.67
*Hypoglycemia is considered to be present with any documented in-hospital episode of glucose,70mg/dL.
†Per every 10 mg/dL increment of CV. ‡In comparison with 1st tertile. xPer every 10–percentage point in-
crement of SD.
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of GV during the hospital stay. In addi-
tion, setting a relatively high limit for the
hypoglycemia analyses (any episode,70
mg/dL), instead of only severe episodes
(,40 mg/dL), supports the hypothesis
that GV has a deleterious effect on LOS
and mortality independent of the effect
of hypoglycemia itself.
The possible mechanisms implicated
in the pathophysiology of GV include an
overproduction of reactive oxygen spe-
cies through the same four pathways
involved in the tissue-damaging effects
of hyperglycemia (28). Quagliaro et al.
(14) showed that endothelial adhesion
molecules activated during inﬂammation
are increased in the presence of oscillat-
ing glucose levels versus stable high glu-
cose. Endothelial function was also
shown to be further impaired in rats
who were exposed to oscillating levels
of blood glucose when compared with
those with persistent hyperglycemia
(29). Monnier et al. (15) studied the ef-
fects of GV on oxidative stress in patients
with diabetes. With the use of continuous
glucose monitoring (CGM), they con-
cluded that GV had a more speciﬁc trig-
gering effect on oxidative stress than did
chronic sustained hyperglycemia.
We acknowledge the following limi-
tations in this study. The data were
collected retrospectively, thus limiting
the acquisition of records of factors such
as nutritional status, ﬂuids, certain med-
ications (such as steroids), and time of
administration of insulin, which may
have inﬂuenced the assessed GV. Al-
though the CCI was used to account
for a range of coexisting medical condi-
tions, other variables, such as smoking
status or serum creatinine, were not in-
cluded in the analyses.
The lack of glucose monitoring pro-
tocols with standardized frequency for
patients in the general wards is probably
the most important limitation of our
study. As suggested by Hermanides
et al. (19), there are added beneﬁts from
using indexes such as MAG to more ac-
curately assess GV across time. Because of
the heterogeneity of our glucose data,
however, these indices could not be
properly calculated. Thus, although the
results of this study provide an estimate
of overall GV during the hospital stay,
these do not differentiate subjects with
gradual glucose changes from those
with acute swings.
In addition, because our study was
performed in a single Veterans Affairs
medical center, the sample consisted of
mainly older white males, which pre-
cludes our results from generalization.
Limitations inherent in the sample could
also possibly explain the high rate of
diabetes and the lack of a signiﬁcant
association between hyperglycemia and
the measured outcomes found in this
study. The inclusion criteria used in this
study resulted in a sample in which most
subjects had an important component
of hyperglycemia (MHG 182.4 6 56.9
mg/dL) and .85% admissions were of
patients with a previous diagnosis of di-
abetes. It could be therefore speculated
that in a more heterogeneous sample
including a larger group of euglycemic
subjects, hyperglycemia would have
been signiﬁcantly associated with worse
outcomes.
Studies examining the possible causes
of increased GV in hospitalized patients
are not available to date. It has been
suggested that sliding scale insulin ther-
apy could be a factor that directly would
lead to increased GV (30). In this study,
however, we did not ﬁnd an association
between the use of human regular insulin
as a sole regimen and higher GV. This
could have been the result of lack of in-
formation regarding dosing, times of
Figure 1dA: Mean LOS (days 6 SE) and 90-day mortality (% 6 SE) of increasing SD tertiles
across two MHG categories (90–180 mg/dL and $180 mg/dL). B: Mean LOS (days 6 SE) and
90-day mortality (%6 SE) of increasing CV tertiles across two MHG categories (90–180 mg/dL
and $180 mg/dL). For linear trend, P , 0.05 for all series except the 90-day mortality in the
MHG $180 mg/dL group for SD (P = 0.77) and CV (P = 0.24).
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administration of insulin, and nutritional
status. In addition, in light of the lack of
insulin protocols used in the facility for
the studied dates, a potential association
between the multiple combinations of
other antidiabetic regimens and GV could
not be explored.
Our results have important clinical
implications. The increased LOS ob-
served in the patients with higher GV
may indicate a signiﬁcant increase in
morbidity and could directly affect the
cost of care. Patients in the group of
highest GV (SD .66 mg/dL and
CV .37%) stayed an average of an addi-
tional 3 days in the hospital, with an esti-
mated additional cost of $7,500 U.S. in
hospital expenses relative to those with
low GV (SD, 42 mg/dL or CV ,25%)
(31). Moreover, high inpatient GV may
be an underestimated factor associated
with increased risk of death within 90
days from hospital discharge that should
alert clinicians about high-risk patients.
Although analysis of SD and CV from
four-point glucose proﬁles provides a
measurable estimate of GV, studies com-
paring the quality of this information
against data obtained from CGM are not
available for noncritically ill hospitalized
patients. For a better understanding of the
association between GV and clinical out-
comes in hospitalized patients, future
prospective studies therefore should use
CGM technology to allow more direct
measurement of GV.
In conclusion, our results indicate
that increased GV is independently asso-
ciated with longer LOS and greater
90-day mortality in noncritically ill hos-
pitalized patients. Prospective studies
with CGM to investigate more fully the
relationship between GV, mean glucose,
and hypoglycemia and clinical outcomes
in this patient population are necessary
before new strategies for inpatient glyce-
mic control can be recommended.
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